Multiple myeloma In Rwanda: The need for further research
Dr Soff presents, at a press conference at ASH 2015, results from a quality assessment study looking at enoxaparin dose reduction for thrombocytopenia in patients with cancer.
Read the news story for more information.
Multiple myeloma In Rwanda: The need for further research
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
ATRA-ATO regimen with idarubicin could become the new standard of care in high-risk acute promyelocytic leukaemia
Ponatinib is better than imatinib for frontline treatment of newly diagnosed Ph+ acute lymphoblastic leukaemia
Isatuximab in combination with pomalidomide and dexamethasone shows promising efficacy in 2nd line RRMM
ASCO 2024: Two studies report on isatuximab combos in transplant-ineligible patients with newly diagnosed multiple myeloma
Daratumumab plus bortezomib/lenalidomide/dexamethasone in transplant-eligible patients with NDMM: MRD analysis
Relapsed refractory multiple myeloma
The evolving paradigm in management of Multiple Myeloma